Charlotte Nichols
MP for Warrington North · Labour · United Kingdom
“Does the Minister accept that although people co-infected with HIV and hepatitis C represent only around 7% of those on infected blood support schemes, they make up roughly 14% of those receiving special category support, because of the disproportionate harm caused by early hepatitis C treatments?”
“I completely agree with the hon. Gentleman’s points, and those of the victims whose voices he is bringing to the fore. Does he agree that both the proposals by the Government and the amendment to the Victims and Courts Bill that was agreed to in the other place, which says that victims will have the right to access a transcript of the jud…”
“In the spirit of cross-party consensus, I commend both the hon. Member on securing this debate and the hon. Member for Richmond Park (Sarah Olney) on her campaigning work in this area.”
“The violence against women and girls sector has not had the opportunity to come together to discuss it, and the Government’s framing and narrative has been to pit survivors and defendants against each other in a way that I think is deeply damaging.”
“I thought long and hard about speaking today. I will allow right hon. and hon. Members from the legal profession to make the legal arguments better than I can, and will allow Members who rightly have procedural or rights-based concerns for defendants, which I share, to raise them. I trust that those points will be satisfactorily covered.”
“Shamefully, the tariffs have not been uprated in line with inflation since 2012 and have no eligibility for non-contact sexual offences, which can cause significant and lasting harm.”
The complete record
Every one of 600 lines we hold for Charlotte Nichols, in date order, each linked to its source. Free to read, in full, without an account. Page 6 of 12.
“Concerns were raised with us about poor or, in some cases, illegal practices, ranging from tax malpractice and fraud to dangerous health and safety arrangements and sexual harassment. We were repeatedly warned about a lack of adequate medical supplies and supervision. The inquiry received one submission that drew on a wider understanding of promotions in the north of England and suggested that expertise to identify and treat injuries was “only intermittently present” at shows. I am particularly grateful to Professor Claire Warden at Loughborough for her insights. She highlighted how the approaches of local councils can differ remarkably in just a few miles, even if the language used in licensing forms is similar.”
“On the matter of policies and procedures, we were pleased to work recently with Loughborough University, with support from the PlayFight wrestling school, on the first ever parliamentary conference on wrestling, and we are developing a guide to better practice, which we hope will be informed by those in the industry, to help others across the British wrestling world. We were told during the all-party group’s inquiry that the lack of a definition, whether as sport or art, created a minefield when it came to insurance and licensing. We have concerns that for promotions, the licensing system may still be somewhat of a minefield, particularly when people are navigating different licensing schemes. We know for certain that there are issues in this wholly unregulated industry.”
“Both Sport England and Arts Council England have funded wrestling, but neither particularly wants the responsibility of being a home for English wrestlers or wrestling. Our APPG took the view—a novel one, I think—that for wrestling schools, the designation should be sporting, whereas promotions should be classed as theatrical. As the report made clear, defining promotions as theatrical entertainment opens up conversations about licensing, representation, governance, and improved policies and procedures.”
“Fans often remark that, in the UK, one could go to a wrestling event nearly every night of the week, if one wanted to do so, and pack out the weekends with entertainment. Shows run in schools, gyms, entertainment venues and even fields. Of course, to run events safely and to a standard, there is a licensing requirement—or at least there should be. In April 2021, the APPG released what constitutes the first ever thorough, systemic parliamentary analysis of wrestling. One of its key themes is the categorisation of wrestling as either theatre or sport. That might appear a simple matter, but wrestling involves serious athleticism alongside dramatic performance. There are competitions, albeit predetermined ones.”
“Among our number we have fans of World Wrestling Entertainment, All Elite Wrestling, Impact, New Japan Pro-Wrestling and, most importantly, British promotions such as the all-women show EVE, PROGRESS, Revolution Pro Wrestling, NORTH, TNT and Renaissance, as well as start-ups such as the all-new women’s promotion, Galzilla, which literally hatched from an egg on the stage at the amazing Wrestival festival in London this year. Those wrestling promotions span the country, as do wrestling schools. In my constituency of Warrington North, we have our own wrestling academy, the Warrington Wrestling Academy, and I look forward to many Warringtonians making their way to the major leagues in years to come.”
“I beg to move, That this House has considered the matter of professional wrestling event licensing and guidance. It is a pleasure to serve under your chairship, Mr Betts. The all-party parliamentary group on wrestling is without a doubt one of the most joyous and exciting in this institution. I am proud to be an active vice-chair, and I pay tribute to my hon. Friend the Member for Pontypridd (Alex Davies-Jones) and the hon. Member for Bolsover (Mark Fletcher)—our co-chairs—and to our group secretary, Danny Stone. They have brought serious and appropriate discussion of wrestling into this place, where too often in the past it was mocked.”
“Similarly, we were told that in the past inter-promotional wars were waged between those wrestling companies that had clocked the importance of boxing-related restrictions on a licence and those that had not, with one company forcing another to forfeit a licensing opportunity. The constant association of wrestling with boxing is deeply problematic. The concern is always that the local licensing process is so complex and likely to lead to rejection that wrestling shows are occurring around the country in unregulated venues or without licensing. We in the APPG would like to see some consistency in approaches to licensing, enhanced confidence for promoters so that they can hold a show, and certainty for all about how wrestling should be categorised by local authorities and what the requirements are or should be.”
“That is not to say that boxing is always violent or problematic, but the lumping together of boxing and wrestling for licensing purposes has certainly caused problems. Wrestling has no concussive intent—although, as my hon. Friend the Member for Pontypridd said, of course concussive injuries occur—whereas the sole intent of boxing is to knock out the opponent. To conflate the two for licensing purposes makes very little sense. We were told that some years ago that Tower Hamlets turned down wrestling events on advice from the local police, who had taken a decision based on boxing events.”
“In 2002, during a debate on what would become the Licensing Act 2003, the other place was told: “we know that boxing and wrestling and their audiences present a significant issue with regard to public safety. As the noble Baroness said, the relationship between wrestling and its audience is particularly engaging, and its showmanship can engage the audience very directly. But, as has been known for many decades, boxing also engages passions. From time to time, boxing bouts have aroused as much vigour in the audience as in those participating in the ring—in some cases, rather more than occurs in the ring.” —[ Official Report, House of Lords, 12 December 2002; Vol. 642, c. 391.] Wrestling and boxing are far from the same; I speak as someone who has now been to multiple wrestling shows, large and small.”
“Cam Tilley, who wrestles under the moniker Kamille Hansen—and who is a former researcher in this place—pointed out to us, through the dissertation that she has just finished on related issues, that these matters have already been discussed in this House. In the 1960s, questions were posed about the prohibition of wrestling performances by women, with the reply that there was no evidence to suggest that the issue was widespread enough to merit action and that this was ultimately a matter for local authorities to decide on as part of their licensing powers. However, London County Council had already fallen into the mode of effectively banning women’s wrestling in venues that it had licensed in the previous decades.”
“In June 2021, we wrote to the then Minister of State at the Home Office, Lord Stephen Greenhalgh, to seek his assistance with the implementation of the recommendation in the APPG’s report, which was welcomed at the Dispatch Box by the Government. We asked about the possibility of widening the temporary events notice licence guidance to include health and safety, and other minimum standards protocols, for wrestling suppliers, and sought guidance on arrangements for Scotland and Northern Ireland. The APPG followed up on the letter, but to no avail, so I am delighted that the Minister will be able to update us today on what progress there has been and what plans might be in place. I hope the Minister can also demonstrate a degree of updated thinking.”
“The evidence I mentioned fed into the APPG’s inquiry and our recommendation that: “For any sized promotion, having even limited safety measures in place should be part of the key requirements for running an event, either through requirements to use council property, the TENs licence or a governing body and in the absence of the latter, we recommend that the Home Office brings forward proposals to broaden TENs licence guidance to include health and safety and other minimum standards protocols for wrestling suppliers. We recognise that the legislation is different in Scotland and Northern Ireland, but we request that both devolved administrations assess whether their current licencing rules adequately cover wrestling promotions”.”
“I could not agree more. I know that British wrestling is doing a lot of work with the Rugby Football League, for example, on concussion protocols. Unfortunately, despite the pre-determined nature of what happens in a wrestling ring, injuries and accidents are common, so medics should be there to make sure that such risks can be mitigated as far as possible.”
“The Minister refers to information from other sectors that can be used as a starting point, but conflating wrestling and boxing is part of the problem, as I highlighted in my speech. Does he not think that it is time that we had some simple, clear, basic guidance from the Home Office to local councils about how to license a safe wrestling event?”
“Having spoken to local councillors, I know that a number of wrestling events take place in Warrington. They find that lack of clarity troubling because many do not have the knowledge and understanding of the wrestling sector that the Minister does, so they are not sure what they are meant to be looking at when determining whether an event should be licensed. They need something that makes it clear to them; a tick-box exercise when making such determinations would be beneficial. Does the Minister agree?”
“I thank the Backbench Business Committee for having the political courage and will—those are, sadly, too often lacking in this place —to grant us this important debate so that we may move ahead on rescheduling psilocybin. Now it is the Government’s turn to show that political courage and will. Psilocybin’s current status as a schedule 1 drug is incommensurate with the evidence of its harm and utility. I beg the Government to support our motion and finally, finally right the historic wrong of its scheduling.”
“Of all of the psychedelic compounds that show promise in this area, psilocybin has the lowest risk profile across all metrics, so there is little reason not to reschedule it but plenty of reasons to make the change as soon as possible. The overwhelming scientific consensus is that psilocybin does not pose a major risk to the individual, to public health or to social order. Its schedule 1 designation is not morally, medically or economically appropriate. We are supported in our call today not only by politicians from across the House, but by the Royal College of Psychiatrists, the Campaign Against Living Miserably, the Conservative Drug Policy Reform Group, Drug Science, Heroic Hearts, Clusterbusters and SANE, among many other organisations.”
“The motion would make no difference to the laws around recreational use or supply of psilocybin or magic mushrooms. Further, there is no evidence of diversion of schedule 2 substances from clinical research. Use of psilocybin-containing mushrooms is low, and there is no evidence of users developing a dependency. As psilocybin mushrooms grow wild throughout the United Kingdom, psilocybin does not represent an opportunity for profit-motivated gangs and criminal individuals. These proposals do not risk increasing drug-related harms but will allow us to assess and access the benefits of psilocybin as a substance.”
“In Australia, from 1 July this year, “medicines containing the psychedelic substances psilocybin and MDMA can be prescribed by specifically authorised psychiatrists for the treatment of certain mental health conditions.” In Canada, healthcare practitioners may be able to access psilocybin for emergency treatment under a special access program when a clinical trial is not available or suitable. We have charitable organisations in this country, such as Heroic Hearts, which take veterans abroad to be able to access treatment that they should be able to get in this country on our NHS. We have scientists, including the brilliant Dr Ben Sessa, leaving the country to pursue research and treatment abroad. That is utterly, utterly shameful. The real-world data from those countries will only make avoiding change in the UK even less justifiable.”
“Mental health costs the UK £117.9 billion a year—around 5% of GDP—yet that is not nearly enough money to address our current crisis. Waiting lists for specialist treatment are often years long. There is both a moral and economic imperative for the Government to act. We are being left behind as a nation. Some US states have legalised the use of psilocybin in mental health treatment. In 2018 it was granted “breakthrough therapy” status for depression by the United States Food and Drug Administration, expediting the research and approval process, with expected approval by the FDA in 2024.”
“Depression is one of the most socially, medically and economically burdensome diseases of the modern world. It is the single largest cause of global disability and the leading contributor to suicide. An average of 18 people take their own lives every day. Up to one third of people with depression do not respond to multiple courses of medication; an estimated 1.2 million adults in the UK live with treatment-resistant depression. The direct treatment and unemployment costs to the UK associated with depression in 2020 have been estimated at £10 billion. The human and economic burden of that condition is profound, and there are clear benefits to supporting development of therapies that may be effective where all other treatments have failed.”
“The evidence shows that psilocybin, as with other psychedelics, can be such an effective treatment for PTSD that following a successful course of psychedelic-assisted therapy, many patients no longer even fulfil the diagnostic criteria any more—they are all but cured. But this Home Office, and its scheduling policy, which says against all the evidence that this is not allowed, is stopping that. It feels like institutional cruelty to condemn us to our misery when there are proven safe and effective treatment options if only the Government would let us access them. Just as that is one story—my own experience—consider the millions of people in this country and around the world living with the same, with no hope that things can or will ever get better.”
“Even at its best, it is a living hell. There is nothing I would not give, nothing I would not do, to go back to who I was before my diagnosis. My experience is not unique. This is the reality of living with a serious mental health condition. I am making it through as best I can because of the love and support of friends, colleagues and psychiatric intervention, but I know that, just as I am a million miles better than I have been, and there are many more good days than bad these days, I could easily relapse because of something I can neither plan for nor prevent. I am hopeful that this sort of treatment may offer a light at the end of a very dark tunnel and finally give me my life back.”
“Members to consider for a moment what it is like living with a condition such as PTSD and the myriad subtle and unsubtle ways my body lets me down: having to put my best face on and go into a meeting after a panic attack; having the energy to make it through our long working hours after a virtually sleepless night plagued by night terrors, where I try to fight my attacker off me and wake up covered in bruises; seeing someone who looks like my attacker on a tube platform and feeling a terror so acute that I want to jump in front of the oncoming train to make it stop; going for walks until I am exhausted and my feet are bleeding in order to burn through the nervous energy that fizzes up inside me; finding myself in dangerous situations and being more vulnerable as a result; hearing a car going past playing the song that was playing when my PTSD began and vomiting; dissociating and losing time; being angry, messy and erratic; crying at everything and nothing; being snappy with my loved ones and becoming convinced that ending my own life would be a kindness to all those who have had to deal with me throughout the worst period of my PTSD, from my staff to my family.”
“I manage it through a combination of a powerful serotonin and norepinephrine reuptake inhibitor, Venlafaxine, taken daily, benzodiazepines taken for sleep and to stave off a dissociative episode if I am triggered by something, and regular therapy, following an almost month-long period as a psychiatric inpatient, having been sectioned in 2021 for my own safety. I am not telling the House this for sympathy, but because I hope my experience can be illustrative of just how debilitating a condition such as PTSD is. We all know that being an MP can be a difficult job at the best of times. However, I ask hon.”
“Psilocybin has been shown in numerous studies globally to have a profound and lasting effect over placebos for a range of different mental health conditions including treatment-resistant depression, post-traumatic stress disorder, anorexia nervosa and addiction. I want to talk first about one of those conditions, PTSD. I have referred previously to living with PTSD, and that is where my interest in the potential promise of psilocybin as a treatment first began—so please consider this a declaration of interest, Mr Deputy Speaker. I was first diagnosed almost two years ago, after being the victim of a crime, and I cannot overstate the impact it has had on my life. PTSD is a condition that I can expect to live alongside potentially indefinitely, and that can only ever be managed. It is a condition that has, for me, proved almost fatal.”
“Psychiatrists tell me that psychedelics are the best clinical tool and the best bit of psychiatric equipment they have, altering states of consciousness to allow for deeper processing and exploration of trauma and opening a therapeutic window where treatment can work, versus sub-optimal treatments with maintenance medications and substandard psychotherapies. Moving on to patients, there is not a single other field where we would accept a 90% failure rate as acceptable, yet in mental health treatment that is where we are. There are a number of mental health conditions, including borderline personality disorder, that we seem to be satisfied with having no proper treatments or cures for.”
“It is dangerous, immoral and unethical, and it is frankly offensive to both psychiatrists and their patients that we seem to think that as politicians we know better because of some moral panic 50 years ago. Multi-criteria decision analysis shows the comparative harms of various different kinds of drugs. Psilocybin is physiologically non-toxic and consistently found to be one of the safest controlled drugs, with the broader category of psychedelic compounds it falls into considered relatively safe physiologically and not drugs of dependence. The idea that psychedelics, including psilocybin, are dangerous is a myth, created and perpetuated to justify keeping them illegal.”
“At a recent seminar at the Royal Society of Chemistry with some of the country’s most eminent neuroscientists, psychopharmacologists and psychiatrists, I spoke to countless researchers who have run into the same issues, making their research either needlessly more expensive or so prohibitively difficult to do that it has had to be abandoned. There is a huge credibility gap between psychiatry and politics for that reason; psychiatrists cannot understand why, at a time when we claim to be listening to the experts in the field of health, and when this country is facing a mental health crisis, we in Westminster are satisfied with doing nothing on this issue. Why do we set up expert bodies and not listen to them?”
“He says that “in order to undertake my research, I would have had to spend upwards of £20,000 applying for Home Office Schedule 1 licences and retrofitting my laboratory to the correct security standards. Meanwhile, I can work with heroin, cocaine, and methamphetamine with no qualms. In light of this, I had to modify my experiment to instead investigate the effects of ketamine. I find it shocking that this government is willing to throw life science research under the bus and push life scientists out of this country with an outdated and downright illegitimate understanding of the medical benefits psilocybin can provide. Please do what you can to fix this!” That is just one example.”
“While current legislation does not preclude scientific research with the drugs, it does make them significantly more difficult, time-consuming and costly to study. I will share with the House just one example of this, from Rudy, a psychology PhD student whose thesis is investigating psychopharmaceutical treatments for addiction—a noble avenue of study, as I am sure we would all agree. Rudy was first motivated to undertake this research after reading incredible findings that psilocybin administration was associated with sustained nicotine cessation in humans, with 80% of participants abstinent after 6 months. Rudy wanted to see whether those results could be replicated to treat other addiction disorders. However, he ran into problems due to the schedule 1 status of psilocybin.”
“Modern psychedelic research began when Albert Hofmann first synthesized lysergic acid diethylamide, or LSD, in 1938, causing something of an explosion in interest among psychiatrists and psychologists, with studies from the period showing the safety and efficacy of psychedelics, including psilocybin, in treating a whole range of psychiatric conditions. However, all that progress was stalled by the counter-cultural movement of the 1960s, which ultimately led to the criminalisation of the drugs. Since then we have been in stasis, until in recent years something like a psychedelic renaissance has taken place among researchers. Today, there are serious and considerable barriers to legitimate research associated with the schedule 1 regulations.”
“The earliest evidence of psychedelic use can be found in a cave in the Tassili-N’Ajjer region of the Sahara desert in Algeria, with a mural depicting what is referred to as the “mushroom man” or “mushroom shaman”, a bee-headed figure with mushrooms identified as Psilocybe mairei, native to the region, sprouting from his body. The mural has been dated as being between 7,000 and 9,000 years old. The Selva Pascuala mural in a cave in Spain features mushrooms that researchers believe to be Psilocybe hispanica, a local species of psychedelic mushroom, and is dated as being approximately 6,000 years old. We can also date back to the 13th century western scientists first discussing the use of psychedelics in healthcare in Latin America. None of this is new.”
“The evidential basis for psilocybin’s current status as a schedule 1 substance has never been reviewed since it was first controlled more than 50 years ago, and there is an urgent and medically justified need to reschedule psilocybin under the Misuse of Drugs Regulations 2001. It is unethical to deny that any longer. A review of the evidence of psilocybin’s harms and utility should be undertaken immediately, with a view to rescheduling it. The use of psychedelics in medicine is not novel; they have been used throughout human history to treat the sick, from peyote ceremonies in Mexico to ayahuasca in the Amazon basin, and the San Pedro cactus in Peru.”
“Psilocybin is a psychoactive substance found in more than 50 species of fungi, including many native varieties of mushroom that grow wild across the UK. There is a certain irony in the fact that this debate follows on from the debate on access to nature, because in many respects our debate is also about that. Psilocybin is a naturally occurring substance and produces a window of neuroplasticity that lasts for a number of hours. When administered in a controlled environment with psychotherapeutic intent by trained professionals, psilocybin could be a powerful and effective tool to help treat society’s most complex mental health conditions, and that is what we call on the Government to make possible.”
“I beg to move, That this House welcomes the development of treatment options in mental health; further notes there have been no new pharmacological treatments for depression, with the exception of Esketamine, in over 30 years; recognises that psilocybin, a naturally occurring compound, has the potential to revolutionise the treatment of many of the world’s most hard to treat psychiatric conditions such as depression, PTSD, OCD, addiction and anorexia nervosa; recognises that no review of the evidence for psilocybin’s current status under UK law has ever been conducted; regrets that psilocybin is currently more controlled than heroin under the most stringent class and schedule under UK law which is significantly stalling research; and calls on the Government to take steps to conduct an urgent review of the evidence for psilocybin’s current status as Schedule 1 under the Misuse of Drugs Regulations 2001 with a view to rescheduling, initially for research purposes only, in order to facilitate the development of new mental health treatments and enable human brain research for the benefit of researchers, patients and the life sciences sector in the UK, and to deliver His Majesty’s Government’s commitment to be world-leading in its approach, with evidence-led and data-driven interventions, and building the evidence base where necessary.”
“The Minister refers to marketing authorisation. In this case, psilocybin, as we have discussed, is something that grows in mushrooms across the UK. Is the Minister suggesting that people would be able to access psilocybin only if it were in another substance?”
“The Minister keeps referring to medicines containing psilocybin. He does not seem to understand that psilocybin is the medicine, in and of itself. It does not need to be added to something else to make it work. This is why we are running into the issue. The Government keep telling us about a licensing regime in which there is a requirement to add something to the compound in order to make it some sort of novel substance, rather than looking at the substance that already exists and, as we have said, has been used for thousands of years with demonstrated safety and efficacy. Will the Minister talk about psilocybin, rather than medicines containing psilocybin?”
“Question put and agreed to. Resolved, That this House welcomes the development of treatment options in mental health; further notes there have been no new pharmacological treatments for depression, with the exception of Esketamine, in over 30 years; recognises that psilocybin, a naturally occurring compound, has the potential to revolutionise the treatment of many of the world’s most hard to treat psychiatric conditions such as depression, PTSD, OCD, addiction and anorexia nervosa; recognises that no review of the evidence for psilocybin’s current status under UK law has ever been conducted; regrets that psilocybin is currently more controlled than heroin under the most stringent class and schedule under UK law which is significantly stalling research; and calls on the Government to take steps to conduct an urgent review of the evidence for psilocybin’s current status as Schedule 1 under the Misuse of Drugs Regulations 2001 with a view to rescheduling, initially for research purposes only, in order to facilitate the development of new mental health treatments and enable human brain research for the benefit of researchers, patients and the life sciences sector in the UK, and to deliver His Majesty’s Government’s commitment to be world-leading in its approach, with evidence-led and data-driven interventions, and building the evidence base where necessary.”
“I thank all Members who came to support the debate. Like my hon. Friend the Member for Reigate (Crispin Blunt)—he is a friend—I am disappointed in the Government’s response; yet again, we see a real lack of urgency from them on this issue. As we have heard, the ACMD review has been ongoing since 2017. In that time, at least 40,000 people have taken their own lives. I am grateful for the fact that the Minister said he will take back the content of today’s discussion to the Minister for Crime, Policing and Fire, the right hon. Member for Croydon South (Chris Philp), who should have been here today but unfortunately was not, because I am really keen that we should finally progress this issue. I thank all Members who took part in the debate to make the case clearly and cogently to the Government that we cannot accept their inertia any longer.”
“When will we see substantial Government time for horizon scanning for an industrial strategy that is fit for the future, instead of tinkering around the edges as we get left further behind?”
“In the two years since this Government recklessly disbanded the Industrial Strategy Council, other economies with a more proactive approach to decarbonisation, artificial intelligence and automation, sciences such as genomics and cyber are fast overtaking us. Not only are we not a world leader in the technologies in which we should and could be a world leader, but we are barely even a world follower at this point. In recent weeks, countries such as Sweden have showcased to the Business, Energy and Industrial Strategy Committee fully zero-carbon steel and battery gigafactories at commercial scale, on which this country has no realistic pathway even to begin work.”
“As the House will know, this week is MS Awareness Week. Early diagnosis and treatment of MS are vital to delay disability progression and help those with the condition to manage it, yet, currently, 13,000 people have been waiting more than a year for a neurology appointment after GP referral. A recent study suggested that the UK comes a shameful 44th out of 45 European countries for neurologists per head of population. When will the Government bring forward a strategy to attract, recruit and retain the neurology workforce?”
“Today’s statement is incredibly light on substance and actual commitments. There is no reason why the Government could not begin verifying and registering those affected in preparation for the publication of the final report and for the swift delivery of compensation. The Minister’s statement reiterates the need for pace, yet there is no commitment to even beginning that work, nor is there a vague timeline for when it might begin. At a time when victims are dying every week and we are in a sustained cost of living crisis, justice delayed is justice denied. Why are the Government causing further unnecessary delays with their inaction? Have the victims and their families not already suffered more than enough?”
“Among the most harrowing parts of Baroness Casey’s report, she quotes a serving police officer who says of rape, “you may as well say it’s legal in London.” However, that is not just an issue for London or the Metropolitan Police. This Government have allowed the national charge rate for rape to drop to an abysmal, historic low of 1.6%. Does the Home Secretary accept that this is a national problem, and that it is her responsibility to fix it so that victims can expect justice from our justice system?”
“A number of companies and sectors, including companies in the oil and gas sector, have made more profit over the last few years than they know what to do with. While my constituents face the highest tax burden in decades, little seems to have been done to tax those giants with the broadest shoulders more. Sticking plasters are not enough. The Government could have gone much further and been much fairer. Politics is about priorities, and we can see from this Budget today that the people's priorities have been overlooked and millions will understandably be feeling short-changed as a result.”
“There was an opportunity to reform the apprenticeship levy to make it work for businesses, for industry and for apprentices themselves, but this returnerships proposal that no one asked for is what we have instead. That was an opportunity missed. There was also a missed opportunity to improve our bus sector—buses are the most used form of transport in the country—and a missed opportunity to do more for our small businesses: the Federation of Small Businesses has described this Budget as irrelevant to the 5.5 million-strong small business community. There was a further missed opportunity to reform business rates radically to bolster our high streets. However, the biggest missed opportunity of all was the failure to make those who can most afford to pay do just that.”
“I welcome the measures to support leisure centres—I recently led an Adjournment debate on the need for them—and the differential for draught beer, which will also be greatly welcomed by the all-party parliamentary group on pubs, which I chair. However, while there are aspects that I welcome, this Budget has been lacking in big-vision ideas to get our country moving. Halving inflation does not mean prices coming down; it only means that they rise more slowly. Without a proper pay rise for the country, too many of the essentials of everyday life will still be out of reach for too many, and our local food banks and charity sector will still be stretched far beyond capacity.”
“In the meantime, however, we will continue to lose, on average, 18 people a day to suicide, and our veterans and victims of crime will continue to suffer needlessly with post-traumatic stress disorder. The funds that the Chancellor committed today to the Office for Veterans’ Affairs and to the suicide prevention fund, which involves voluntary, community and social enterprise organisations, could be working much harder and going much further if we would only commit ourselves to what colleagues across parties have been calling for: a drug scheduling policy based on evidence, rather than stigma, misinformation and political expediency.”
“Nor does the lack of anything for social care help families who are caring for parents and children or grandchildren at the same time to get back into the workforce. That is not nearly good enough, especially at a time when my local council is having to spend 70% of its budget on statutory care services—a situation that will only get worse over time with an ageing population with increasingly complex care needs. The announcement of reforms to the medicines approval process is welcome, as it means that patients should receive access to emerging medicines, including psychedelics, sooner than they otherwise might. MDMA and psilocybin are due to receive approval from the US Food and Drug Administration in 2024 and will be approved later this year in Australia. Hopefully, UK patients will gain access simultaneously or soon afterwards.”